Real-World Outcomes of Ocrelizumab and Ofatumumab Treatment in Pediatric-Onset Multiple Sclerosis.

Ocrevus (ocrelizumab) - Roche

Kesimpta (ofatumumab subcutaneous) - Novartis, Genmab

http://www.ncbi.nlm.nih.gov/pubmed/42768184

Alexandra B Kornbluh; Claire Har; Hayley Roper; Ilana Kahn; Vivien X Xie Cherng

Sep 23, 2026